Woods J A, Knauer T E, Lamb R G
Biochim Biophys Acta. 1981 Dec 23;666(3):482-92. doi: 10.1016/0005-2760(81)90310-6.
Streptozotocin-induced diabetes produced a significant rise in rat serum and liver triacylglycerol content and hepatic triacylglycerol biosynthesis measured in vivo. Microsomes, isolated from the livers of streptozotocin-exposed animals (2-72h), exhibited an increased capacity to incorporate sn-[1,3-(14)C]glycerol 3-phosphate into neutral lipid (diacylglycerol and triacylglycerol) in the presence of ATP, CoA and palmitate. The streptozotocin-induced elevation of microsomal neutral lipid production was accompanied by a corresponding rise in the activity of microsomal phosphatidate phosphohydrolase (4-fold after 72 h of streptozotocin exposure). Diabetic-dependent increases in acylglycerol formation, phosphatidate phosphohydrolase activity and serum triacylglycerol and fatty acid levels were reversed by administering insulin (10 units protamine zinc/kg) at 16-h intervals (three separate doses( beginning 24 h after streptozotocin exposure. However, the diabetic-related rise in hepatic triacylglycerol content was only partially corrected by insulin administration. Streptozotocin-relate increases in liver triacylglycerol biosynthesis and phosphatidate phosphohydrolase activity we associated with alterations in plasma factors, since homogenates of hepatocyte monolayers exposed (18h) to plasma isolated from diabetic (72 h exposure to streptozotocin) animals exhibit an increased capacity to incorporate sn-[1,3-(14)C]glycerol 3-phosphate into triacylglycerol compared to homogenates of cells exposed to plasma from control (non-fasted) animals. The importance of these plasma factors in altering hepatic acylglycerol formation was also supported by the observation that hepatocyte monolayers exposed to a mixture of plasma isolated from normal (non-fasted) animals and plasma components elevated in diabetes (glucagon, glucose, oleate and ketones) showed increases in triacylglycerol formation which were similar to those produced by exposure to diabetic plasma. Additional studies demonstrated that fatty acids (oleate) appeared to be the agent primarily responsible for the diabetic plasma-induced rise in monolayer triacylglycerol biosynthesis and phosphatidate phosphohydrolase activity.
链脲佐菌素诱导的糖尿病使大鼠血清和肝脏三酰甘油含量显著升高,并使体内肝脏三酰甘油生物合成增加。从链脲佐菌素处理动物(2 - 72小时)肝脏中分离出的微粒体,在ATP、辅酶A和棕榈酸存在的情况下,将sn-[1,3-(14)C]甘油3 - 磷酸掺入中性脂质(二酰甘油和三酰甘油)的能力增强。链脲佐菌素诱导的微粒体中性脂质生成增加伴随着微粒体磷脂酸磷酸水解酶活性相应升高(链脲佐菌素处理72小时后增加4倍)。通过每隔16小时注射胰岛素(10单位精蛋白锌/千克)(链脲佐菌素处理24小时后开始,共三个单独剂量),可逆转糖尿病相关的酰基甘油形成增加、磷脂酸磷酸水解酶活性增加以及血清三酰甘油和脂肪酸水平升高。然而,胰岛素给药仅部分纠正了糖尿病相关的肝脏三酰甘油含量升高。链脲佐菌素相关的肝脏三酰甘油生物合成增加和磷脂酸磷酸水解酶活性增加与血浆因子的改变有关,因为暴露于糖尿病动物(链脲佐菌素处理72小时)血浆18小时的肝细胞单层匀浆与暴露于对照(非禁食)动物血浆的细胞匀浆相比,将sn-[1,3-(14)C]甘油3 - 磷酸掺入三酰甘油的能力增强。这些血浆因子在改变肝脏酰基甘油形成中的重要性还得到以下观察结果的支持:暴露于正常(非禁食)动物血浆和糖尿病中升高的血浆成分(胰高血糖素、葡萄糖、油酸和酮体)混合物的肝细胞单层,其三酰甘油形成增加,与暴露于糖尿病血浆所产生的增加相似。进一步的研究表明,脂肪酸(油酸)似乎是导致糖尿病血浆诱导的单层三酰甘油生物合成和磷脂酸磷酸水解酶活性升高的主要因素。